The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization
- 1 January 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 29, 115865
Abstract
No abstract availableKeywords
Funding Information
- Pfizer
This publication has 22 references indexed in Scilit:
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory DiseasesJournal of Medicinal Chemistry, 2014
- Drug discovery considerations in the development of covalent inhibitorsBioorganic & Medicinal Chemistry Letters, 2014
- JAK Kinases in Health and Disease: An UpdateThe Open Rheumatology Journal, 2012
- Bruton’s Tyrosine Kinase Inhibitors: Approaches to Potent and Selective Inhibition, Preclinical and Clinical Evaluation for Inflammatory Diseases and B Cell MalignanciesJournal of Medicinal Chemistry, 2012
- Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for SchizophreniaACS Medicinal Chemistry Letters, 2012
- Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for painBioorganic & Medicinal Chemistry Letters, 2011
- The resurgence of covalent drugsNature Reviews Drug Discovery, 2011
- Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug ResistanceChemBioChem, 2010
- Mechanism-Based Inhibition: Deriving KI and kinact Directly from Time-Dependent IC50 ValuesSLAS Discovery, 2009
- Novel Mechanistic Class of Fatty Acid Amide Hydrolase Inhibitors with Remarkable SelectivityBiochemistry, 2007